{"disease": "melanoma", "drug": "AZD5363", "Q1": {"selection": "No", "clinicaltrial_references": [{"study_summary": {"title": "NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas", "NCTID": "NCT02465060", "drug_for_treatment": ["adavosertib", "Afatinib", "binimetinib", "capivasertib", "copanlisib", "Crizotinib", "dabrafenib", "Dasatinib", "defactinib", "erdafitinib", "AZD4547", "ipatasertib", "larotrectinib", "Nivolumab", "osimertinib", "palbociclib", "pertuzumab", "GSK2636771", "relatlimab", "sapanisertib", "Sunitinib", "trametinib", "omipalisib", "trastuzumab", "ulixertinib", "HhAntag691"], "indication": "Advanced Refractory Solid Tumors or Lymphomas", "result_summary_sentence": "No results posted yet.", "phase": "Phase II", "risk_level": "High", "positive_or_negative": "", "population_summary": "Patients with advanced refractory solid tumors or lymphomas", "has_results": false, "sample_size": 6452, "start_year": 2015, "this_year-start_year": 8, "complete_year": null}, "scoring": {"mechanism": {"score": 85, "explanation": "The investigational drugs target specific genetic mutations known to drive cancer progression. Many of these targets have been validated in other studies and are relevant to the disease biology."}, "clinical_evidence": {"score": 40, "explanation": "Although the study is ongoing and has enrolled a large number of patients, no results have been posted yet. This limits the ability to assess clinical efficacy directly."}, "safety_predictability": {"score": 70, "explanation": "The safety profiles of the investigational drugs are generally well-characterized based on their mechanisms and previous studies. However, the combination of multiple targeted therapies may introduce new safety concerns."}, "trial_quality": {"score": 75, "explanation": "The trial design is robust, with a large sample size and a focus on genetic testing to guide therapy. This should allow for meaningful signal detection and strong endpoints."}, "result_status": {"score": 45, "category": "ongoing_long_term_incomplete", "explanation": "The study has been ongoing for 8 years without posted results, which exceeds normal development timelines for Phase II trials."}, "target_drug_importance": {"score": 90, "role": "major", "explanation": "The investigational drugs are central to the study outcome, as the trial aims to match patients with therapies based on their genetic profiles."}, "overall_confidence": {"score": 65, "explanation": "While the mechanistic rationale and trial design are strong, the lack of posted results and the long duration of the study without completion reduce overall confidence."}}, "nct_id": "NCT02465060"}, {"study_summary": {"title": "IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors", "NCTID": "NCT05039801", "drug_for_treatment": ["IACS-6274", "Bevacizumab", "Paclitaxel"], "indication": "Advanced Solid Tumors", "result_summary_sentence": "The study is currently recruiting and has not yet posted results.", "phase": "Phase 1", "risk_level": "High", "positive_or_negative": "", "population_summary": "Patients with advanced solid tumors including chondrosarcoma, endometrial neoplasms, squamous cell carcinoma of head and neck, melanoma, and ovarian neoplasms.", "has_results": false, "sample_size": 60, "start_year": 2021, "this_year-start_year": 2, "complete_year": null}, "scoring": {"mechanism": {"score": 75, "explanation": "IACS-6274 targets a relevant pathway in cancer biology, and similar mechanisms have shown promise in oncology. Bevacizumab and Paclitaxel are well-established agents with known efficacy in various cancers."}, "clinical_evidence": {"score": 50, "explanation": "The study is in Phase 1 and currently recruiting, so early clinical signals are not yet available. The lack of posted results limits the ability to assess clinical efficacy."}, "safety_predictability": {"score": 60, "explanation": "Expected toxicities based on the mechanisms of IACS-6274, Bevacizumab, and Paclitaxel are predictable. However, detailed safety data are not yet available from this study."}, "trial_quality": {"score": 65, "explanation": "The trial design includes dose-escalation and combination arms, which are appropriate for Phase 1 studies. The endpoints and inclusion criteria are standard for early-phase oncology trials."}, "result_status": {"score": 70, "category": "ongoing_in_reasonable_term", "explanation": "The study started in 2021 and is still recruiting, which is within a reasonable timeframe for Phase 1 trials."}, "target_drug_importance": {"score": 80, "role": "major", "explanation": "IACS-6274 is the primary experimental agent in the study, with Bevacizumab and Paclitaxel as combination partners. The results will be directly informative for evaluating IACS-6274."}, "overall_confidence": {"score": 65, "explanation": "Moderate confidence in the investigational drug based on the mechanistic rationale and trial design. The lack of clinical results limits higher confidence at this stage."}}, "nct_id": "NCT05039801"}]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro. [https://pubmed.ncbi.nlm.nih.gov/29708815/]", "Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors. [https://pubmed.ncbi.nlm.nih.gov/26490311/]"]}}
{"disease": "melanoma", "drug": "Altretamine", "Q1": {"selection": "No", "clinicaltrial_references": [{"study_summary": {"title": "NM32-2668 in Adult Patients With Selected Advanced Solid Tumors", "NCTID": "NCT06299163", "drug_for_treatment": ["NM32-2668"], "indication": "Selected Advanced Solid Tumors", "result_summary_sentence": "The study was terminated due to a business decision, and no results are available.", "phase": "Phase 1", "risk_level": "High", "positive_or_negative": "Negative", "population_summary": "Adult patients with selected advanced solid tumors including ovarian, fallopian tube, endometrial, lung adenocarcinoma, triple negative breast cancer, liposarcoma, leiomyosarcoma, malignant mesothelioma, melanoma, and renal cell carcinoma.", "has_results": false, "sample_size": 50, "start_year": 2023, "this_year-start_year": 2, "complete_year": 2025}, "scoring": {"mechanism": {"score": 70, "explanation": "NM32-2668 is a tri-specific antibody targeting ROR1, CD3, and HSA. ROR1 is a known target in various solid tumors, and CD3 engagement is a validated approach in immunotherapy. However, the combination of these targets is novel and lacks extensive validation."}, "clinical_evidence": {"score": 20, "explanation": "The study was terminated due to a business decision, and no clinical results are available. This significantly weakens the clinical evidence for NM32-2668."}, "safety_predictability": {"score": 50, "explanation": "Expected toxicities include immune-related adverse events due to CD3 engagement. The safety profile is predictable based on the mechanism, but without clinical data, the actual tolerability remains uncertain."}, "trial_quality": {"score": 60, "explanation": "The trial design includes multiple advanced solid tumor types and is conducted at reputable institutions. However, the termination of the study limits the ability to assess the quality of endpoints and inclusion criteria."}, "result_status": {"score": 20, "category": "completed_no_result", "explanation": "The study is marked as terminated with no posted results, which significantly lowers confidence in the investigational drug."}, "target_drug_importance": {"score": 80, "role": "major", "explanation": "NM32-2668 is the primary experimental agent in the study, making its evaluation central to the study outcome."}, "overall_confidence": {"score": 40, "explanation": "Overall confidence is low due to the lack of clinical results and the termination of the study. While the mechanistic rationale is strong, the absence of clinical evidence and the study's termination significantly impact the confidence level."}}, "nct_id": "NCT06299163"}, {"nct_id": "NCT05179174", "model_output": ["blood sample examination"]}]}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "melanoma", "drug": "Atezolizumab", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma [https://clinicaltrials.gov/study/NCT04356729]"]}, "Q2": {"selection": "Positive result in vivo result", "literature_references": ["Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model. [https://pubmed.ncbi.nlm.nih.gov/34119742/]", "A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy. [https://pubmed.ncbi.nlm.nih.gov/34054817/]"]}}
{"disease": "melanoma", "drug": "Avelumab", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["Exercise to Boost Response to Checkpoint Blockade Immunotherapy [https://clinicaltrials.gov/study/NCT05358938]", "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors [https://clinicaltrials.gov/study/NCT03228667]"]}}
{"disease": "melanoma", "drug": "Axitinib", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma [https://clinicaltrials.gov/study/NCT04640545]", "Axitinib + Ipilimumab in Advanced Melanoma [https://clinicaltrials.gov/study/NCT04996823]", "Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma [https://clinicaltrials.gov/study/NCT00094107]"]}}
{"disease": "melanoma", "drug": "Bevacizumab", "Q1": {"selection": "Completed phase II with positive result", "clinicaltrial_references": ["A Randomized Phase II Study of Ipilimumab With or Without Bevacizumab in Unresectable Stage III or Stage IV Melanoma [https://clinicaltrials.gov/study/NCT01950390]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["The possibility of angiogenesis inhibition in cutaneous melanoma by bevacizumab-loaded lipid-chitosan nanoparticles. [https://pubmed.ncbi.nlm.nih.gov/36058987/]", "177Lu-DOTA-Bevacizumab: Radioimmunotherapy Agent for Melanoma. [https://pubmed.ncbi.nlm.nih.gov/27748184/]", "VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma. [https://pubmed.ncbi.nlm.nih.gov/27549123/]"]}}
{"disease": "melanoma", "drug": "Binimetinib", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["A Phase II Randomized Study of Encorafenib, Binimetinib, and Nivolumab in Patients With Melanoma Brain Metastases [https://clinicaltrials.gov/study/NCT04221438]", "Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma [https://clinicaltrials.gov/study/NCT05304546]"]}}
{"disease": "melanoma", "drug": "Camrelizumab", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "melanoma", "drug": "Capecitabine", "Q1": {"selection": "No", "clinicaltrial_references": ["QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy [https://clinicaltrials.gov/study/NCT03167177]"]}, "Q2": {"selection": "Positive result in animal study", "literature_references": ["DCA increases the antitumor effects of capecitabine in a mouse B16 melanoma allograft and a human non-small cell lung cancer A549 xenograft. [https://pubmed.ncbi.nlm.nih.gov/24043136/]"]}}
{"disease": "melanoma", "drug": "Carboplatin", "Q1": {"selection": "Completed phase I with positive result (or FDA-Approved for other diseases)", "clinicaltrial_references": ["An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors [https://clinicaltrials.gov/study/NCT01618136]"]}}
{"disease": "melanoma", "drug": "Carfilzomib", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "melanoma", "drug": "Cemiplimab", "Q1": {"selection": "In phase III", "clinicaltrial_references": ["Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma [https://clinicaltrials.gov/study/NCT07223411]"]}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "melanoma", "drug": "Cisplatin", "Q1": {"selection": "No", "clinicaltrial_references": [{"title": "A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.", "NCTID": "NCT05661955", "drug_for_treatment": ["BGB-A445", "Tislelizumab"], "indication": "Advanced Solid Tumors", "result_summary_sentence": "The study is ongoing and has not yet posted results.", "phase": "Phase 1b/2", "risk_level": "Moderate", "positive_or_negative": "", "population_summary": "Participants with select advanced solid tumors including Carcinoma, Transitional Cell; Carcinoma, Renal Cell; and Melanoma.", "has_results": false, "sample_size": 200, "start_year": 2022, "this_year-start_year": 1, "complete_year": null}, {"title": "Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients", "NCTID": "NCT01336270", "drug_for_treatment": ["Dacarbazine", "Cisplatin", "B-raf inhibitor"], "indication": "Melanoma", "result_summary_sentence": "The study aimed to characterize immune cell infiltrates in melanoma patients and their impact on disease outcomes.", "phase": "Observational", "risk_level": "Low", "positive_or_negative": "Neutral", "population_summary": "Patients with melanoma, including those with larger tumors, cutaneous metastasis, stage III undergoing lymph node dissection, and stage IV receiving chemotherapy.", "has_results": false, "sample_size": 217, "start_year": 2011, "this_year-start_year": 14, "complete_year": 2025}, {"title": "A Phase II Study of Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy in Advanced Mucosal Melanoma", "NCTID": "NCT06041724", "drug_for_treatment": ["Envafolimab", "Recombinant Human Endostatin", "First-line Chemotherapy"], "indication": "Advanced Mucosal Melanoma", "result_summary_sentence": "The study is not yet recruiting and has no posted results.", "phase": "II", "risk_level": "High", "positive_or_negative": "", "population_summary": "Patients with histology and pathology confirmed advanced mucosal melanoma, aged 18 years or older, with ECOG PS 0-1, and meeting specific laboratory criteria.", "has_results": false, "sample_size": 30, "start_year": 2023, "this_year-start_year": 0, "complete_year": null}]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Assessment of pharmacodynamic interactions of two-drug combinations of five selected cytostatics in an in vitro model of human melanoma: an isobolographic analysis. [https://pubmed.ncbi.nlm.nih.gov/41222692/]", "Knockdown of Derlin-1 Represses Cellular Oncogenic Activities in Uveal Melanoma, Enhances its Chemosensitivity to Cisplatin and Reduces Cancer Stem Cell Potential. [https://pubmed.ncbi.nlm.nih.gov/40883028/]", "In Vitro Evaluation of Cytotoxic and Pro-Apoptotic Effects of Hesperidin Alone and in Combination with Cisplatin on Human Malignant Melanoma Cell Line (A431). [https://pubmed.ncbi.nlm.nih.gov/40573250/]", "Inhibition of Sox4 Increases the Sensitivity of Drug-resistant Melanoma Cells to Cisplatin through the P38 Signaling Pathway. [https://pubmed.ncbi.nlm.nih.gov/40396326/]"]}}
{"disease": "melanoma", "drug": "Cobimetinib", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. [https://clinicaltrials.gov/study/NCT05768178]", "Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases [https://clinicaltrials.gov/study/NCT03175432]", "Vemurafenib Plus Cobimetinib in Metastatic Melanoma [https://clinicaltrials.gov/study/NCT02414750]"]}}
{"disease": "melanoma", "drug": "Dabrafenib", "Q1": {"selection": "Completed phase II with positive result", "clinicaltrial_references": ["A Phase II Study of Dabrafenib, Trametinib, and Hydroxychloroquine in Patients with Advanced BRAF V600E/K Mutant Melanoma [https://clinicaltrials.gov/study/NCT04527549]", "A Phase I Study of Omipalisib in Combination with Dabrafenib and Trametinib in Patients with Advanced Melanoma [https://clinicaltrials.gov/study/NCT01989585]", "BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients [https://clinicaltrials.gov/study/NCT03944356]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Comparative Analysis of the Effect of the BRAF Inhibitor Dabrafenib in 2D and 3D Cell Culture Models of Human Metastatic Melanoma Cells. [https://pubmed.ncbi.nlm.nih.gov/38936891/]", "Inhibitory effect of imperatorin on dabrafenib metabolism in vitro and in vivo. [https://pubmed.ncbi.nlm.nih.gov/38964639/]"]}}
{"disease": "melanoma", "drug": "Docetaxel", "Q1": {"selection": "No", "clinicaltrial_references": ["A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) [https://clinicaltrials.gov/study/NCT00600496]", "A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) [https://clinicaltrials.gov/study/NCT02817633]", "Thalidomide and Docetaxel in Treating Patients With Advanced Cancer [https://clinicaltrials.gov/study/NCT00049296]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Assessment of pharmacodynamic interactions of two-drug combinations of five selected cytostatics in an in vitro model of human melanoma: an isobolographic analysis. [https://pubmed.ncbi.nlm.nih.gov/41222692/]", "Comparative analysis of mangiferin against conventional drugs for skin cancer and inflammation: integrating in-silico and in-vitro studies. [https://pubmed.ncbi.nlm.nih.gov/39654271/]", "Antiproliferative effects of LY-2183240 combined with various chemotherapeutic drugs in an isobolographic in vitro model of malignant melanoma. [https://pubmed.ncbi.nlm.nih.gov/39187040/]", "Development and Evaluation of Docetaxel-Loaded Nanostructured Lipid Carriers for Skin Cancer Therapy. [https://pubmed.ncbi.nlm.nih.gov/39065657/]", "Chemo-immunotherapy by nanoliposomal epacadostat and docetaxel combination to IDO1 inhibition and tumor microenvironment suppression. [https://pubmed.ncbi.nlm.nih.gov/38870880/]", "Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing. [https://pubmed.ncbi.nlm.nih.gov/38482021/]", "Evaluation of ABT-751, a novel anti-mitotic agent able to overcome multi-drug resistance, in melanoma cells. [https://pubmed.ncbi.nlm.nih.gov/38226983/]", "The Blocking of Drug Resistance Channels by Selected Hydrophobic Statins in Chemoresistance Human Melanoma. [https://pubmed.ncbi.nlm.nih.gov/38136555/]", "AM1172 (a hydrolysis-resistant endocannabinoid analog that inhibits anandamide cellular uptake) reduces the viability of the various melanoma cells, but it exerts significant cytotoxic effects on healthy cells: an in vitro study based on isobolographic analysis. [https://pubmed.ncbi.nlm.nih.gov/38019413/]", "Malaria Biomimetic for Tumor Targeted Drug Delivery. [https://pubmed.ncbi.nlm.nih.gov/37435892/]", "Daphnetin, a Coumarin with Anticancer Potential against Human Melanoma: In Vitro Study of Its Effective Combination with Selected Cytostatic Drugs. [https://pubmed.ncbi.nlm.nih.gov/37371063/]", "Fraxetin Interacts Additively with Cisplatin and Mitoxantrone, Antagonistically with Docetaxel in Various Human Melanoma Cell Lines-An Isobolographic Analysis. [https://pubmed.ncbi.nlm.nih.gov/36613654/]", "Additive Interactions between Betulinic Acid and Two Taxanes in In Vitro Tests against Four Human Malignant Melanoma Cell Lines. [https://pubmed.ncbi.nlm.nih.gov/36077036/]", "Bismuth Lipophilic Nanoparticles (BisBAL NP) Inhibit the Growth of Tumor Cells in a Mouse Melanoma Model. [https://pubmed.ncbi.nlm.nih.gov/35168526/]", "Immunotherapeutic HCW9218 augments anti-tumor activity of chemotherapy via NK cell-mediated reduction of therapy-induced senescent cells. [https://pubmed.ncbi.nlm.nih.gov/35051615/]", "Docetaxel and Lidocaine Co-Loaded (NLC-in-Hydrogel) Hybrid System Designed for the Treatment of Melanoma. [https://pubmed.ncbi.nlm.nih.gov/34683846/]", "Oxygen-carrying nanoparticle-based chemo-sonodynamic therapy for tumor suppression and autoimmunity activation. [https://pubmed.ncbi.nlm.nih.gov/33908449/]", "Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma. [https://pubmed.ncbi.nlm.nih.gov/31839677/]", "Tumor-Targeted Drug and CpG Delivery System for Phototherapy and Docetaxel-Enhanced Immunotherapy with Polarization toward M1-Type Macrophages on Triple Negative Breast Cancers. [https://pubmed.ncbi.nlm.nih.gov/31721331/]", "PHA-Based Thermogel as a Controlled Zero-Order Chemotherapeutic Delivery System for the Effective Treatment of Melanoma. [https://pubmed.ncbi.nlm.nih.gov/35030745/]"]}}
{"disease": "melanoma", "drug": "Doxorubicin", "Q1": {"selection": "No", "clinicaltrial_references": ["Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies [https://clinicaltrials.gov/study/NCT02419495]", "A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) [https://clinicaltrials.gov/study/NCT05824975]", "A Phase I/II Study of Intrahepatic Delivery of Doxorubicin Hydrochloride Adsorbed to Magnetic Beads in Patients with Cancer Metastatic to the Liver [https://clinicaltrials.gov/study/NCT00041808]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Doxorubicin Intercalated Co-Al Layered Double Hydroxide Nanocarrier With pH-Responsive Controlled Release and Selective Melanoma Suppression: Toward Next-Generation Nanotherapeutics. [https://pubmed.ncbi.nlm.nih.gov/40964945/]", "Distinct In Vitro Effects of Liposomal and Nanostructured Lipid Nanoformulations with Entrapped Acidic and Neutral Doxorubicin on B16-F10 Melanoma and Walker 256 Carcinoma Cells. [https://pubmed.ncbi.nlm.nih.gov/40733112/]"]}}
{"disease": "melanoma", "drug": "Encorafenib", "Q1": {"selection": "Completed phase III with positive result", "clinicaltrial_references": ["Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US [https://clinicaltrials.gov/study/NCT05260684]"]}, "Q2": {"selection": "", "literature_references": []}}
{"disease": "melanoma", "drug": "Estramustine", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Blocking of collagenase secretion by estramustine during in vitro tumor cell invasion. [https://pubmed.ncbi.nlm.nih.gov/2846150/]", "Estramustine phosphate-reduced proliferation of murine and human cell lines and murine transplantable tumors. [https://pubmed.ncbi.nlm.nih.gov/3860896/]"]}}
{"disease": "melanoma", "drug": "Floxuridine", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "melanoma", "drug": "Fluorouracil", "Q1": {"selection": "No", "clinicaltrial_references": ["TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers [https://clinicaltrials.gov/study/NCT04485013]", "A Phase 1/2 Study of DuoBody-CD40x4-1BB in Patients With Advanced Solid Tumors [https://clinicaltrials.gov/study/NCT04083599]", "Phase I Study of Lenalidomide, Bevacizumab, Sorafenib, Temsirolimus, Oxaliplatin, Leucovorin, Fluorouracil (FOLFOX) [https://clinicaltrials.gov/study/NCT01183663]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Quercetin Enhances 5-Fluorouracil-Driven Cytotoxicity Dose-Dependently in A375 Human Melanoma Cells. [https://pubmed.ncbi.nlm.nih.gov/39768392/]", "5-Fluorouracil- and Sesamol-Loaded Transliposomal Gel for Skin Cancer: In Vitro, Ex Vivo, and Dermatokinetic Evaluation. [https://pubmed.ncbi.nlm.nih.gov/40028080/]"]}}
{"disease": "melanoma", "drug": "Gemcitabine", "Q1": {"selection": "No", "clinicaltrial_references": ["A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors. [https://clinicaltrials.gov/study/NCT06889610]", "Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases [https://clinicaltrials.gov/study/NCT03093909]", "Study of Metastatic Ocular Melanoma [https://clinicaltrials.gov/study/NCT00168870]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Core-shell nanofibers for localized melanoma therapy delivering Pioglitazone nanoemulsions and gemcitabine dual loaded system. [https://pubmed.ncbi.nlm.nih.gov/40760166/]", "Gemcitabine nanoparticles promote antitumor immunity against melanoma. [https://pubmed.ncbi.nlm.nih.gov/30388589/]"]}}
{"disease": "melanoma", "drug": "Hydroxyurea", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Checkpoint kinase 1 inhibitor + low-dose hydroxyurea efficiently kills BRAF inhibitor- and immune checkpoint inhibitor-resistant melanomas. [https://pubmed.ncbi.nlm.nih.gov/37614154/]", "Determination of Selected Isoquinoline Alkaloids from Chelidonium majus, Mahonia aquifolium and Sanguinaria canadensis Extracts by Liquid Chromatography and Their In Vitro and In Vivo Cytotoxic Activity against Human Cancer Cells. [https://pubmed.ncbi.nlm.nih.gov/37047332/]", "Determination of Cytotoxic Activity of Sanguinaria canadensis Extracts against Human Melanoma Cells and Comparison of Their Cytotoxicity with Cytotoxicity of Some Anticancer Drugs. [https://pubmed.ncbi.nlm.nih.gov/33804614/]", "Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine. [https://pubmed.ncbi.nlm.nih.gov/31044505/]"]}}
{"disease": "melanoma", "drug": "Ipilimumab", "Q1": {"selection": "FDA-Approved to melanoma", "clinicaltrial_references": ["Phase III Randomized Study of Ipilimumab With or Without Interferon Alfa-2b in Patients With High-Risk Melanoma [https://clinicaltrials.gov/study/NCT01274338]", "A Randomized Phase II Study of Ipilimumab, Nivolumab, and Sargramostim in Patients With Advanced Melanoma [https://clinicaltrials.gov/study/NCT02339571]", "Exercise and Checkpoint Blockade Immunotherapy [https://clinicaltrials.gov/study/NCT05358938]"]}}
{"disease": "melanoma", "drug": "Lapatinib", "Q1": {"selection": "Failed in any phases", "clinicaltrial_references": ["Lapatinib in Stage IV Melanoma With ERBB4 Mutations [https://clinicaltrials.gov/study/NCT01264081]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Lapatinib dysregulates HER2 signaling and impairs the viability of human uveal melanoma cells. [https://pubmed.ncbi.nlm.nih.gov/38021158/]"]}}
{"disease": "melanoma", "drug": "Lomustine", "Q1": {"selection": "No", "clinicaltrial_references": ["Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients [https://clinicaltrials.gov/study/NCT00527657]", "A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the Brain [https://clinicaltrials.gov/study/NCT01563614]", "Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma [https://clinicaltrials.gov/study/NCT00072345]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Carnosic acid impedes cell growth and enhances anticancer effects of carmustine and lomustine in melanoma. [https://pubmed.ncbi.nlm.nih.gov/29789400/]", "Structure-based design of nitrosoureas containing tyrosine derivatives as potential antimelanoma agents. [https://pubmed.ncbi.nlm.nih.gov/11960664/]", "Spin labelled nitrosoureas and triazenes and their non-labelled clinically used analogues--a comparative study on their physicochemical properties and antimelanomic effects. [https://pubmed.ncbi.nlm.nih.gov/11165083/]", "New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance. [https://pubmed.ncbi.nlm.nih.gov/11007934/]", "The effects of different antineoplastic agents and of pretreatment by modulators on three melanoma lines. [https://pubmed.ncbi.nlm.nih.gov/9452267/]", "Azelaic acid was sensitizing effect in the chemotherapeutic treatment of several melanoma cell lines. [https://pubmed.ncbi.nlm.nih.gov/9125756/]", "A phase I trial of weekly lomustine in patients with advanced cancer. [https://pubmed.ncbi.nlm.nih.gov/8275432/]", "The usefulness of human tumor cell lines in the study of chemosensitivity. A study of malignant melanomas. [https://pubmed.ncbi.nlm.nih.gov/7309286/]", "In vitro sensitivity of human melanoma xenografts to cytotoxic drugs. Correlation with in vivo chemosensitivity. [https://pubmed.ncbi.nlm.nih.gov/7216540/]"]}}
{"disease": "melanoma", "drug": "MK-2206", "Q1": {"selection": "Failed in any phases", "clinicaltrial_references": ["A Phase I Study of MK-2206 and Hydroxychloroquine in Patients With Advanced Solid Tumors [https://clinicaltrials.gov/study/NCT01480154]", "A Phase I Study of MK-2206 and AZD6244 in Patients With Advanced Melanoma [https://clinicaltrials.gov/study/NCT01519427]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["C57BL/6 congenic mouse NRAS(Q61K) melanoma cell lines are highly sensitive to the combination of Mek and Akt inhibitors in vitro and in vivo. [https://pubmed.ncbi.nlm.nih.gov/31251472/]", "PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro. [https://pubmed.ncbi.nlm.nih.gov/29708815/]", "Rictor regulates the vasculogenic mimicry of melanoma via the AKT-MMP-2/9 pathway. [https://pubmed.ncbi.nlm.nih.gov/28699701/]", "Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma. [https://pubmed.ncbi.nlm.nih.gov/24490764/]"]}}
{"disease": "melanoma", "drug": "Melphalan", "Q1": {"selection": "In phase I", "clinicaltrial_references": ["Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases [https://clinicaltrials.gov/study/NCT04812470]", "Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma [https://clinicaltrials.gov/study/NCT07183852]", "Isolated Limb Perfusion With Melphalan and Doxorubicin for Extremity Melanoma and Sarcoma [https://clinicaltrials.gov/study/NCT02507076]"]}, "Q2": {"selection": "Positive result in animal study", "literature_references": ["Isolated limb perfusion with melphalan activates interferon-stimulated genes to induce tumor regression in patients with melanoma in-transit metastasis. [https://pubmed.ncbi.nlm.nih.gov/32002296/]", "Isolated Limb Perfusion With Melphalan Triggers Immune Activation in Melanoma Patients. [https://pubmed.ncbi.nlm.nih.gov/30560089/]", "Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin. [https://pubmed.ncbi.nlm.nih.gov/25762540/]", "SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma. [https://pubmed.ncbi.nlm.nih.gov/24281418/]", "Synergistic inhibition of malignant melanoma proliferation by melphalan combined with ultrasound and microbubbles. [https://pubmed.ncbi.nlm.nih.gov/21459032/]"]}}
{"disease": "melanoma", "drug": "Niclosamide", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Combination of niclosamide and quinacrine inactivates Akt/HK2/Cyclin D1 axis mediated by glucose deprivation towards the inhibition of melanoma cell proliferation. [https://pubmed.ncbi.nlm.nih.gov/37187020/]", "Niclosamide inhibits epithelial-mesenchymal transition with apoptosis induction in BRAF/ NRAS mutated metastatic melanoma cells. [https://pubmed.ncbi.nlm.nih.gov/36870549/]", "Quality by design steered development of Niclosamide loaded liposomal thermogel for Melanoma: In vitro and Ex vivo evaluation. [https://pubmed.ncbi.nlm.nih.gov/36198344/]", "Low doses of niclosamide and quinacrine combination yields synergistic effect in melanoma via activating autophagy-mediated p53-dependent apoptosis. [https://pubmed.ncbi.nlm.nih.gov/35460941/]", "The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma in vitro and in vivo. [https://pubmed.ncbi.nlm.nih.gov/28529629/]"]}}
{"disease": "melanoma", "drug": "Nivolumab", "Q1": {"selection": "FDA-Approved to melanoma", "clinicaltrial_references": ["QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy [https://clinicaltrials.gov/study/NCT03167177]", "A Randomized Phase II Study of Ipilimumab, Nivolumab, and Sargramostim in Patients With Advanced Melanoma [https://clinicaltrials.gov/study/NCT02339571]", "Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery [https://clinicaltrials.gov/study/NCT03405155]", "A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma [https://clinicaltrials.gov/study/NCT06581406]"]}}
{"disease": "melanoma", "drug": "Olaparib", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma [https://clinicaltrials.gov/study/NCT05524935]", "Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies [https://clinicaltrials.gov/study/NCT02419495]", "A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine [https://clinicaltrials.gov/study/NCT00516802]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["PARP inhibition promotes endothelial-like traits in melanoma cells and modulates pericyte coverage dynamics during vasculogenic mimicry. [https://pubmed.ncbi.nlm.nih.gov/36484652/]", "Influence of onconase in the therapeutic potential of PARP inhibitors in A375 malignant melanoma cells. [https://pubmed.ncbi.nlm.nih.gov/31185226/]", "PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas. [https://pubmed.ncbi.nlm.nih.gov/27705909/]"]}}
{"disease": "melanoma", "drug": "Paclitaxel", "Q1": {"selection": "No", "clinicaltrial_references": ["A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of DuoBody-CD40x4-1BB in Subjects With Advanced Solid Tumors [https://clinicaltrials.gov/study/NCT04083599]", "SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma [https://clinicaltrials.gov/study/NCT06743126]", "RAPA-201 in Patients With Malignant Melanoma [https://clinicaltrials.gov/study/NCT06708455]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Dual-targeted albumin nanoparticles for the Co-delivery of low-dose paclitaxel and PCSK9 inhibitor in melanoma treatment. [https://pubmed.ncbi.nlm.nih.gov/41080729/]", "Novel Autotaxin Inhibitor ATX-1d Significantly Enhances Potency of Paclitaxel-An In Silico and In Vitro Study. [https://pubmed.ncbi.nlm.nih.gov/39339280/]", "Antiproliferative effects of LY-2183240 combined with various chemotherapeutic drugs in an isobolographic in vitro model of malignant melanoma. [https://pubmed.ncbi.nlm.nih.gov/39187040/]"]}}
{"disease": "melanoma", "drug": "Pembrolizumab", "Q1": {"selection": "FDA-Approved to melanoma", "clinicaltrial_references": ["QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy [https://clinicaltrials.gov/study/NCT03167177]", "Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma [https://clinicaltrials.gov/study/NCT04318717]", "A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancer [https://clinicaltrials.gov/study/NCT05383170]", "Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma [https://clinicaltrials.gov/study/NCT06697301]"]}}
{"disease": "melanoma", "drug": "Pimasertib", "Q1": {"selection": "Completed phase II with positive result", "clinicaltrial_references": ["Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma [https://clinicaltrials.gov/study/NCT01693068]"]}}
{"disease": "melanoma", "drug": "Plerixafor", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "melanoma", "drug": "Radium Ra 223 dichlo", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "melanoma", "drug": "Ramucirumab", "Q1": {"selection": "Completed phase II with negative result", "clinicaltrial_references": ["A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma [https://clinicaltrials.gov/study/NCT00533702]"]}, "Q2": {"selection": "Rarely discussed", "literature_references": ["Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. [https://pubmed.ncbi.nlm.nih.gov/19513949/]"]}}
{"disease": "melanoma", "drug": "Refametinib", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "melanoma", "drug": "Relatlimab", "Q1": {"selection": "Completed phase III with positive result", "clinicaltrial_references": ["A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma [https://clinicaltrials.gov/study/NCT03470922]"]}}
{"disease": "melanoma", "drug": "SGI-1027", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "melanoma", "drug": "Sabutoclax", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": ["Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells. [https://pubmed.ncbi.nlm.nih.gov/21780116/]"]}}
{"disease": "melanoma", "drug": "Selumetinib", "Q1": {"selection": "Failed in any phases", "clinicaltrial_references": ["A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) [https://clinicaltrials.gov/study/NCT00600496]", "Phase I Trial of Cediranib and Selumetinib in Patients With Advanced Solid Tumors [https://clinicaltrials.gov/study/NCT01364051]", "A Phase I Study of Temsirolimus and AZD6244 in Patients With Advanced Melanoma [https://clinicaltrials.gov/study/NCT01166126]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Assessment of pharmacodynamic interactions of two-drug combinations of five selected cytostatics in an in vitro model of human melanoma: an isobolographic analysis. [https://pubmed.ncbi.nlm.nih.gov/41222692/]", "In vitro inhibitory effects of selumetinib on activity of human UDP-glucuronosyltransferases and prediction of in vivo drug-drug interactions. [https://pubmed.ncbi.nlm.nih.gov/38823552/]", "Selumetinib-based therapy in uveal melanoma patient-derived xenografts. [https://pubmed.ncbi.nlm.nih.gov/29774094/]"]}}
{"disease": "melanoma", "drug": "Sintilimab", "Q1": {"selection": "In phase I", "clinicaltrial_references": ["A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma [https://clinicaltrials.gov/study/NCT05572463]", "Real World Study of Four PD-1 Agents in China [https://clinicaltrials.gov/study/NCT03966456]"]}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "melanoma", "drug": "Sirolimus", "Q1": {"selection": "No", "clinicaltrial_references": [{"nct_id": "NCT00600496", "model_output": ["AZD6244 (ARRY-142886)", "Erlotinib", "Temsirolimus", "Docetaxel", "Dacarbazine"]}, {"study_summary": {"title": "A Phase I/II Study of Nivolumab, Ipilimumab, and Prednisone in Combination with Sirolimus in Patients with Advanced Malignancies", "NCTID": "NCT05896839", "drug_for_treatment": ["Nivolumab", "Ipilimumab", "Prednisone", "Sirolimus"], "indication": "Advanced Malignancies", "result_summary_sentence": "The study is currently recruiting and has no posted results.", "phase": "Phase I/II", "risk_level": "Moderate", "positive_or_negative": "", "population_summary": "Patients with advanced malignancies including Carcinoma, Basal Cell, Melanoma, and Carcinoma, Merkel Cell.", "has_results": false, "sample_size": 100, "start_year": 2023, "this_year-start_year": 0, "complete_year": null}}, {"study_summary": {"title": "RAPA-201 Therapy of Solid Tumors", "NCTID": "NCT05144698", "drug_for_treatment": ["RAPA-201"], "indication": "PD-(L)1 Resistant Solid Tumors", "result_summary_sentence": "The study is currently recruiting and has not yet posted results.", "phase": "Phase I/II", "risk_level": "Moderate", "positive_or_negative": "", "population_summary": "Patients with PD-(L)1 resistant solid tumors including head and neck cancer, malignant melanoma, small cell carcinoma, and non-small cell lung cancer.", "has_results": false, "sample_size": 60, "start_year": 2021, "this_year-start_year": 4, "complete_year": null}}, {"study_summary": {"title": "Everolimus in Selected Patients with Metastatic Melanoma: Efficacy and Safety Study", "NCTID": "NCT01960829", "drug_for_treatment": ["Everolimus"], "indication": "Metastatic Melanoma", "result_summary_sentence": "The study aims to evaluate the efficacy and safety of Everolimus in patients with metastatic melanoma with mTOR mutations.", "phase": "Phase II", "risk_level": "Moderate", "positive_or_negative": "Unknown", "population_summary": "Patients with metastatic melanoma with mTOR mutations, aged 18-80, ECOG performance status 0-2.", "has_results": false, "sample_size": 60, "start_year": 2013, "this_year-start_year": 10, "complete_year": 2015}}, {"study_summary": {"title": "Sorafenib and Temsirolimus in Treating Patients with Metastatic, Recurrent, or Unresectable Melanoma", "NCTID": "NCT01851408", "drug_for_treatment": ["Sorafenib", "Temsirolimus"], "indication": "Metastatic, Recurrent, or Unresectable Melanoma", "result_summary_sentence": "No results posted yet.", "phase": "Phase II", "risk_level": "High", "positive_or_negative": "", "population_summary": "Patients with metastatic, recurrent, or unresectable melanoma, aged 18 years and older.", "has_results": false, "sample_size": 0, "start_year": 2013, "this_year-start_year": 10, "complete_year": null}}]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Investigation of the effects of mTOR inhibitors rapamycin and everolimus in combination with carboplatin on canine malignant melanoma cells. [https://pubmed.ncbi.nlm.nih.gov/34895222/]"]}}
{"disease": "melanoma", "drug": "Sorafenib", "Q1": {"selection": "Completed phase II with positive result", "clinicaltrial_references": ["Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma [https://clinicaltrials.gov/study/NCT00602576]", "Carboplatin, Paclitaxel, and Sorafenib in Treating Patients With Metastatic Uveal Melanoma [https://clinicaltrials.gov/study/NCT00329641]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["In vitro and in silico study on the effect of carvedilol and sorafenib alone and in combination on the growth and inflammatory response of melanoma cells. [https://pubmed.ncbi.nlm.nih.gov/37323921/]", "Arginase 2 negatively regulates sorafenib-induced cell death by mediating ferroptosis in melanoma. [https://pubmed.ncbi.nlm.nih.gov/36604146/]", "Sorafenib treatment of metastatic melanoma with c-Kit aberration reduces tumor growth and promotes survival. [https://pubmed.ncbi.nlm.nih.gov/34691254/]"]}}
{"disease": "melanoma", "drug": "Spartalizumab", "Q1": {"selection": "Completed phase III with positive result", "clinicaltrial_references": ["A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma [https://clinicaltrials.gov/study/NCT02967692]"]}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "melanoma", "drug": "Talaporfin", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": ["Design, synthesis and biological evaluation of novel 3(1)-hexyloxy chlorin e(6)-based 15(2)- or 13(1)-amino acid derivatives as potent photosensitizers for photodynamic therapy. [https://pubmed.ncbi.nlm.nih.gov/32846322/]"]}}
{"disease": "melanoma", "drug": "Tegafur", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": ["Dipyridamole augments the antitumor effects of fluorinated pyrimidines. [https://pubmed.ncbi.nlm.nih.gov/1567156/]"]}}
{"disease": "melanoma", "drug": "Thiotepa", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": ["The effect of monotherapy and combined therapy with NSC-631570 (ukrain) on growth of low- and high-metastasizing B16 melanoma in mice. [https://pubmed.ncbi.nlm.nih.gov/20817651/]", "Clinical hyperthermia and chemotherapy. [https://pubmed.ncbi.nlm.nih.gov/2648463/]", "The interactions between indomethacin and cytotoxic drugs in mice bearing B-16 melanomas. [https://pubmed.ncbi.nlm.nih.gov/6782621/]"]}}
{"disease": "melanoma", "drug": "Tivozanib", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Receptor tyrosine kinase inhibitor tivozanib regulates cell state plasticity and restores MITF dependency in BRAF wild-type melanoma. [https://pubmed.ncbi.nlm.nih.gov/40550963/]", "Synthesis and structural proof of novel oxazolo[5,4-d]pyrimidine derivatives as potential VEGFR2 inhibitors. In vitro study of their anticancer activity. [https://pubmed.ncbi.nlm.nih.gov/39561438/]"]}}
{"disease": "melanoma", "drug": "Topotecan", "Q1": {"selection": "No", "clinicaltrial_references": [{"study_summary": {"title": "Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies", "NCTID": "NCT02419495", "drug_for_treatment": ["Selinexor"], "indication": "Advanced Malignancies", "result_summary_sentence": "The study aims to evaluate the safety and preliminary efficacy of Selinexor in combination with various standard chemotherapy or immunotherapy agents in patients with advanced malignancies.", "phase": "Phase 1", "risk_level": "High", "positive_or_negative": "", "population_summary": "Patients with advanced malignancies", "has_results": false, "sample_size": 100, "start_year": 2015, "this_year-start_year": 8, "complete_year": null}, "scoring": {"mechanism": {"score": 85, "explanation": "Selinexor is a selective inhibitor of nuclear export (SINE) compound that targets XPO1, a protein involved in the transport of tumor suppressor proteins out of the nucleus. This mechanism is strongly linked to cancer biology, and XPO1 is a validated target in oncology."}, "clinical_evidence": {"score": 40, "explanation": "As the study is in Phase 1 and has no posted results, the clinical evidence is weak. However, early-phase trials are designed to assess safety and preliminary efficacy, which limits the confidence in clinical outcomes at this stage."}, "safety_predictability": {"score": 60, "explanation": "The expected toxicities are based on the mechanism of action of Selinexor and its combination with other agents. While preclinical data suggest manageable safety profiles, the combination with multiple agents increases the complexity of predicting safety."}, "trial_quality": {"score": 70, "explanation": "The trial design includes multiple combination arms, which allows for the assessment of Selinexor's safety and efficacy in various contexts. However, the complexity of the design may pose challenges in interpreting the results."}, "result_status": {"score": 45, "category": "ongoing_long_term_incomplete", "explanation": "The study started in 2015 and has no posted results after 8 years, which exceeds the normal development timelines for a Phase 1 trial. This indicates a long-term incomplete status."}, "target_drug_importance": {"score": 90, "role": "major", "explanation": "Selinexor is the primary experimental agent in this study, and its evaluation is central to the study's outcome."}, "overall_confidence": {"score": 55, "explanation": "The overall confidence in Selinexor for advanced malignancies is moderate. The strong mechanistic rationale and the importance of the drug in the study are balanced by the lack of clinical evidence and the long-term incomplete status of the trial."}}, "nct_id": "NCT02419495"}]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. [https://pubmed.ncbi.nlm.nih.gov/14764461/]", "Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation. [https://pubmed.ncbi.nlm.nih.gov/8892461/]"]}}
{"disease": "melanoma", "drug": "Trametinib", "Q1": {"selection": "Completed phase II with positive result", "clinicaltrial_references": ["A Phase II Study of Dabrafenib, Trametinib, and Hydroxychloroquine in Patients with Advanced BRAF V600E/K Mutant Melanoma [https://clinicaltrials.gov/study/NCT04527549]", "Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation [https://clinicaltrials.gov/study/NCT02231775]"]}}
{"disease": "melanoma", "drug": "Tretamine", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "melanoma", "drug": "Ulixertinib", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["NCI-2015-00054: Various cancers including lymphoproliferative disorders, neuroendocrine tumors, skin neoplasms, ovarian diseases, and others [https://clinicaltrials.gov/study/NCT02465060]", "A Phase II Study of BVD-523 in Metastatic Uveal Melanoma [https://clinicaltrials.gov/study/NCT03417739]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib). [https://pubmed.ncbi.nlm.nih.gov/28939558/]"]}}
{"disease": "melanoma", "drug": "Vemurafenib", "Q1": {"selection": "Completed phase II with positive result", "clinicaltrial_references": ["Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma [https://clinicaltrials.gov/study/NCT01659151]", "Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study [https://clinicaltrials.gov/study/NCT02052193]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Vemurafenib Activates PSMB9 to Induce Ferroptosis via Free Iron Accumulation and Inhibits Melanoma Progression. [https://pubmed.ncbi.nlm.nih.gov/41183120/]", "Eupatilin attenuates vemurafenib resistance through inhibition of ABCB1 in melanoma. [https://pubmed.ncbi.nlm.nih.gov/40628591/]"]}}
{"disease": "melanoma", "drug": "Vinblastine", "Q1": {"selection": "Completed phase III with positive result", "clinicaltrial_references": ["Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma [https://clinicaltrials.gov/study/NCT00003027]", "Effectiveness of Interferon Alfa with/without Combination Chemotherapy + Interleukin-2 for Melanoma [https://clinicaltrials.gov/study/NCT00002882]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. [https://pubmed.ncbi.nlm.nih.gov/19706755/]", "A recombinant peptide, hirudin, potentiates the inhibitory effects of stealthy liposomal vinblastine on the growth and metastasis of melanoma. [https://pubmed.ncbi.nlm.nih.gov/18379065/]"]}}
{"disease": "melanoma", "drug": "Vindesine", "Q1": {"selection": "In phase III", "clinicaltrial_references": ["Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma [https://clinicaltrials.gov/study/NCT00226473]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Pyrazolotriazolopyrimidine derivatives sensitize melanoma cells to the chemotherapeutic drugs: taxol and vindesine. [https://pubmed.ncbi.nlm.nih.gov/12948854/]", "Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression. [https://pubmed.ncbi.nlm.nih.gov/9494534/]", "Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. [https://pubmed.ncbi.nlm.nih.gov/3986806/]"]}}
{"disease": "melanoma", "drug": "WYE-354", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "melanoma", "drug": "talimogene laherparepvec", "Q1": {"selection": "FDA-Approved to melanoma", "clinicaltrial_references": []}}
